{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:12:22Z","timestamp":1784013142085,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.leukres.2019.106176","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T12:38:21Z","timestamp":1561639101000},"page":"106176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens"],"prefix":"10.1016","volume":"84","author":[{"given":"Poonam","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8079-9945","authenticated-orcid":false,"given":"Zhenya","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-2427","authenticated-orcid":false,"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghua","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9916-5064","authenticated-orcid":false,"given":"Xinyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.leukres.2019.106176_bib0005","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"issue":"3-4","key":"10.1016\/j.leukres.2019.106176_bib0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/10428190009148847","article-title":"Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia","volume":"36","author":"Faderl","year":"2000","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.leukres.2019.106176_bib0015","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.1988.6.6.1014","article-title":"A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969","volume":"6","author":"Gaynor","year":"1988","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2019.106176_bib0020","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Gleissner","year":"2002","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2019.106176_bib0025","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2019.106176_bib0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1365-2141.2003.04736.x","article-title":"Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B","volume":"124","author":"Wetzler","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2019.106176_bib0035","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.leu.2403324","article-title":"Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome","volume":"18","author":"Heerema","year":"2004","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.leukres.2019.106176_bib0040","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","article-title":"Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis","volume":"117","author":"Marzocchi","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2019.106176_bib0045","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1365-2141.1996.d01-1968.x","article-title":"Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia","volume":"95","author":"Rieder","year":"1996","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2019.106176_bib0050","first-page":"71","article-title":"A novel three-way Ph variant t(8;9;22) in adult acute lymphoblastic leukemia","volume":"41","author":"Cho","year":"2011","journal-title":"Ann. Clin. Lab. Sci."},{"issue":"22","key":"10.1016\/j.leukres.2019.106176_bib0055","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","article-title":"Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09\/00","volume":"28","author":"Bassan","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2019.106176_bib0060","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","article-title":"Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study","volume":"109","author":"de Labarthe","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2019.106176_bib0065","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2015-03-636548","article-title":"Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia","volume":"126","author":"Kim","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2019.106176_bib0070","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2019.106176_bib0075","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2019.106176_bib0080","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2019.106176_bib0085","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbmt.2011.08.011","article-title":"Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes","volume":"18","author":"Kebriaei","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"15","key":"10.1016\/j.leukres.2019.106176_bib0090","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2013-11-538728","article-title":"Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia","volume":"123","author":"Mizuta","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2019.106176_bib0095","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2019.106176_bib0100","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/leu.2016.231","article-title":"Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2019.106176_bib0105","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2015.03.021","article-title":"Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation","volume":"21","author":"Aldoss","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"4","key":"10.1016\/j.leukres.2019.106176_bib0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ajh.24296","article-title":"Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia","volume":"91","author":"Short","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2019.106176_bib0115","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ajh.10227","article-title":"Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome\/BCR-ABL-positive acute lymphoblastic leukemia in Taiwan","volume":"71","author":"Ko","year":"2002","journal-title":"Am. J. Hematol."},{"issue":"17","key":"10.1016\/j.leukres.2019.106176_bib0120","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2019.106176_bib0125","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","article-title":"Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"95","author":"Milojkovic","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2019.106176_bib0130","first-page":"349","article-title":"Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2\u2019-deoxycytidine","volume":"114","author":"Lubbert","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2019.106176_bib0135","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.leukres.2009.03.004","article-title":"Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy","volume":"33","author":"Balleisen","year":"2009","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.leukres.2019.106176_bib0140","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.24625","article-title":"Poor outcomes associated with +der(22)t(9;22) and -9\/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor","volume":"92","author":"Short","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2019.106176_bib0145","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2019.106176_bib0150","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","article-title":"Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy","volume":"86","author":"Thomas","year":"1999","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.leukres.2019.106176_bib0155","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"Ribera","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.leukres.2019.106176_bib0160","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2019.106176_bib0165","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2014.118588","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.leukres.2019.106176_bib0170","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2019.106176_bib0175","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3892\/ol.2012.1037","article-title":"A novel cytogenetic abnormality t(7;8)(p11.2:q11.2) and a four-way Philadelphia translocation in an imatinib mesylate-resistant chronic myeloid leukemia patient","volume":"5","author":"Al-Achkar","year":"2013","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.leukres.2019.106176_bib0180","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2141.2004.04899.x","article-title":"Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome","volume":"125","author":"El-Zimaity","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"31","key":"10.1016\/j.leukres.2019.106176_bib0185","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","article-title":"IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report","volume":"27","author":"Martinelli","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2019.106176_bib0190","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/cyto.b.21101","article-title":"Detection of minimal residual disease in pediatric acute lymphoblastic leukemia","volume":"84","author":"Gaipa","year":"2013","journal-title":"Cytometry B Clin. Cytom."},{"issue":"10","key":"10.1016\/j.leukres.2019.106176_bib0195","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/cncr.28598","article-title":"Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"120","author":"Jeha","year":"2014","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.leukres.2019.106176_bib0200","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2012-11-466482","article-title":"Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy","volume":"122","author":"Ravandi","year":"2013","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619301213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619301213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:59:29Z","timestamp":1758934769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619301213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":40,"alternative-id":["S0145212619301213"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106176","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106176"}}